Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
RAF265
Cat. No.:
OB0125LY-074
Appearance:
Solid
Purity:
99.5%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
RAF265 is a small molecule compound with potent inhibitory effects on VEGFR2 phosphorylation.
Synonym:
927880-90-8; CHIR-265; RAF265; 1-Methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine
CAS No.:
927880-90-8
Compound CID:
11656518
Formula:
C24H16F6N6O
Formula Weight:
518.41
Specification
Targets & IC50:
C-Raf: 3-60 nM; B-Raf: 3-60 nM; VEGFR2: 30 nM (EC50)
Relative Density:
1.50 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
RAF265 can be used for melanoma and other tumor disease studies related to the RAF signaling pathway.
Library Information
Targets:
Apoptosis; VEGFR; Raf; Autophagy
Receptors:
Apoptosis; Autophagy; B-Raf; Raf; VEGFR; VEGFR2
Pathways:
Angiogenesis; Autophagy; Apoptosis; Tyrosine kinase/adaptors; MAPK
Plate Number:
AOCL-7
Plate Location:
f6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
51.8 mg/mL; 100 mM
Ethanol Max Solubility:
10.4 mg/mL; 20 mM
ALogP:
6.469
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
7
